Evidence map›Paper›PMID 33482670›Full record

ReviewDeutsche medizinische Wochenschrift (1946)2021

[Symptom control in heart failure patients - how to handle GFR decrease and hyperkalaemia].

Vincent Brandenburg, Johann Bauersachs, Michael Böhm, Danilo Fliser, Stefan Frantz, Norbert Frey, Gerd Hasenfuß, Jan T Kielstein

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Deutsche medizinische Wochenschrift (1946), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vincent BrandenburgKlinik für Kardiologie, Nephrologie und Internistische Intensivmedizin, Rhein-Maas-Klinikum, Würselen.
Johann BauersachsKlinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover.
Michael BöhmInnere Medizin III - Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar.
Danilo FliserInnere Medizin IV - Nieren- und Hochdruckkrankheiten, Universitätsklinikum des Saarlandes, Homburg/Saar.
Stefan FrantzMedizinische Klinik und Poliklinik I (Kardiologie, Endokrinologie, Nephrologie, Pneumologie, Intensiv- und Notfallmedizin) Universitätsklinikum Würzburg.
Norbert FreyKlinik für Innere Medizin III (Schwerpunkt Kardiologie, Angiologie und Intensivmedizin), Universitätsklinikum Schleswig-Holstein, Kiel.
Gerd HasenfußHerzzentrum, Abt. Kardiologie und Pneumologie, Universitätsmedizin Göttingen.
Jan T KielsteinKlinik für Nephrologie, Blutreinigung und Rheumatologie, Klinikum Braunschweig.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For heart failure patients with reduced ejection fraction, optimised medication improves symptom control and reduces mortality. Substances influencing the renin-angiotensin-aldosteron-system, so-called RAAS-inhibitors, are the cornerstone of heart failure treatment. This article summarises a consensus between experts in cardiology and in nephrology on a pragmatic approach to manage a drop in glomerular filtration rate and incident hyperkalaemia - the two most common reasons for reducing or discontinuing heart failure medication.

Indexed as

Cardiovascular AgentsGlomerular Filtration RateHeart FailureHumansHyperkalemiaRenin-Angiotensin SystemCardiovascular Agents

Identifiers

PMID33482670
PMCPMC7972821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.